{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:33Z","timestamp":1789688313231,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03338-w","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:09:38Z","timestamp":1756447778000},"page":"5481-5498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Sevim","family":"Bavbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Samaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooran Chand","family":"Kathuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Al Busaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayseer","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Noibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gur","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-6668","authenticated-orcid":false,"given":"Riyad Omar","family":"Al-Lehebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"3338_CR1","unstructured":"Global strategy for asthma management and prevention (2024 update). Global Initiative for Asthma (GINA); 2024. https:\/\/ginasthma.org\/2024-report\/. Accessed Nov 11, 2024."},{"key":"3338_CR2","doi-asserted-by":"publisher","first-page":"2103179","DOI":"10.1183\/13993003.03179-2021","volume":"60","author":"K Mortimer","year":"2022","unstructured":"Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60:2103179.","journal-title":"Eur Respir J"},{"key":"3338_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100502","volume":"14","author":"M Caminati","year":"2021","unstructured":"Caminati M, Morais-Almeida M, Bleecker E, et al. Biologics and global burden of asthma: a worldwide portrait and a call for action. World Allergy Organ J. 2021;14:100502.","journal-title":"World Allergy Organ J"},{"key":"3338_CR4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","volume":"397","author":"J Meghji","year":"2021","unstructured":"Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397:928\u201340.","journal-title":"Lancet"},{"key":"3338_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/lungindia.lungindia_518_23","volume":"41","author":"R Swarnakar","year":"2024","unstructured":"Swarnakar R, Dhar R. Call to action: addressing asthma diagnosis and treatment gaps in India. Lung India. 2024;41:209\u201316.","journal-title":"Lung India"},{"key":"3338_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107674","volume":"228","author":"M Al-Ahmad","year":"2024","unstructured":"Al-Ahmad M, Al Zaabi A, Madkour A, et al. Expert consensus on oral corticosteroids stewardship for the treatment of severe asthma in the Middle East and Africa. Respir Med. 2024;228:107674.","journal-title":"Respir Med"},{"key":"3338_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100647","volume":"15","author":"M Al-Ahmad","year":"2022","unstructured":"Al-Ahmad M, Mobayed H, Al Busaidi N, et al. Severe asthma treatment patterns: a multicenter observational study in the Gulf region. World Allergy Organ J. 2022;15:100647.","journal-title":"World Allergy Organ J"},{"key":"3338_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40733-017-0032-3","volume":"3","author":"D Sol\u00e9","year":"2017","unstructured":"Sol\u00e9 D, Aranda CS, Wandalsen GF. Asthma: epidemiology of disease control in Latin America\u2013short review. Asthma Res Pract. 2017;3:4.","journal-title":"Asthma Res Pract"},{"key":"3338_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.rmed.2018.03.030","volume":"139","author":"D Mungan","year":"2018","unstructured":"Mungan D, Aydin O, Mahboub B, et al. Burden of disease associated with asthma among the adult general population of five Middle Eastern countries: results of the SNAPSHOT program. Respir Med. 2018;139:55\u201364.","journal-title":"Respir Med"},{"key":"3338_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","volume":"199","author":"R Beasley","year":"2019","unstructured":"Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019;199:1471\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"3338_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100760","volume":"16","author":"JF Maspero","year":"2023","unstructured":"Maspero JF, Cruz AA, Beltran CFP, et al. The use of systemic corticosteroids in asthma management in Latin American countries. World Allergy Organ J. 2023;16:100760.","journal-title":"World Allergy Organ J"},{"key":"3338_CR12","doi-asserted-by":"crossref","unstructured":"Dhar R, Rhee CK, Perng D-W, et al. The burden of systemic corticosteroid use in asthma management in Asia. Respirology. 2023;28:744\u201357.","DOI":"10.1111\/resp.14533"},{"key":"3338_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5694\/mja2.50758","volume":"213","author":"M Hew","year":"2020","unstructured":"Hew M, McDonald VM, Bardin PG, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020;213:316\u201320.","journal-title":"Med J Aust"},{"issue":"1","key":"3338_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010182","volume":"25","author":"CY Chen","year":"2023","unstructured":"Chen CY, Wu KH, Guo BC, et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci. 2023;25(1):182. https:\/\/doi.org\/10.3390\/ijms25010182.","journal-title":"Int J Mol Sci"},{"key":"3338_CR15","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448\u201358.","journal-title":"N Engl J Med"},{"key":"3338_CR16","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","volume":"5","author":"K Murphy","year":"2017","unstructured":"Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5:1572-81.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3338_CR17","unstructured":"NUCALA (mepolizumab) prescribing information GSK. 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed Nov 11, 2024."},{"key":"3338_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049","volume":"5","author":"F Roufosse","year":"2018","unstructured":"Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.","journal-title":"Front Med (Lausanne)"},{"key":"3338_CR19","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.","journal-title":"Front Physiol"},{"key":"3338_CR20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"3338_CR21","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","volume":"81","author":"C Domingo Ribas","year":"2021","unstructured":"Domingo Ribas C, Carrillo D\u00edaz T, Blanco Aparicio M, Mart\u00ednez Morag\u00f3n E, Banas Conejero D, S\u00e1nchez Herrero MG. REal worlD Effectiveness and Safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study. Drugs. 2021;81:1763\u201374.","journal-title":"Drugs"},{"key":"3338_CR22","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","volume":"10","author":"C Pilette","year":"2022","unstructured":"Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10:2646\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3338_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","volume":"9","author":"ID Pavord","year":"2021","unstructured":"Pavord ID, Menzies-Gow A, Buhl R, et al. Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine. J Allergy Clin Immunol Pract. 2021;9:1121\u201332.e7.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3338_CR24","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1007\/s12325-024-02967-x","volume":"41","author":"RO Al-Lehebi","year":"2024","unstructured":"Al-Lehebi RO, Al Ahmad M, Maturu VN, et al. Real-world effectiveness of mepolizumab in severe asthma: results from the multi-country, self-controlled NUCALA Effectiveness Study (NEST). Adv Ther. 2024;41:4008\u201331.","journal-title":"Adv Ther"},{"key":"3338_CR25","doi-asserted-by":"crossref","unstructured":"Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, et al. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 2021;9:2702\u201314.","DOI":"10.1016\/j.jaip.2021.01.011"},{"key":"3338_CR26","unstructured":"Pocket guide for asthma management and prevention. (GINA) GIfA; 2021. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Pocket-Guide-2021-V2-WMS.pdf. Accessed 27 Jan 2025."},{"key":"3338_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-022-00306-7","volume":"32","author":"L-P Boulet","year":"2022","unstructured":"Boulet L-P, Lavoie KL, Raherison-Semjen C, Kaplan A, Singh D, Jenkins CR. Addressing sex and gender to improve asthma management. NPJ Prim Care Respir Med. 2022;32:56.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3338_CR28","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0067-2021","volume":"30","author":"NU Chowdhury","year":"2021","unstructured":"Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30:210067. https:\/\/doi.org\/10.1183\/16000617.0067-2021.","journal-title":"Eur Respir Rev"},{"key":"3338_CR29","doi-asserted-by":"publisher","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","volume":"56","author":"T Harrison","year":"2020","unstructured":"Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56:2000151.","journal-title":"Eur Respir J"},{"key":"3338_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100726","volume":"15","author":"ER Bleecker","year":"2022","unstructured":"Bleecker ER, Al-Ahmad M, Bjermer L, et al. Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group. World Allergy Organ J. 2022;15:100726.","journal-title":"World Allergy Organ J"},{"key":"3338_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/atm.atm_469_21","volume":"17","author":"MO Zeitouni","year":"2022","unstructured":"Zeitouni MO, Al-Moamary MS, Coussa ML, et al. Challenges and recommendations for the management of asthma in the Middle East and Africa. Ann Thorac Med. 2022;17:71\u201380.","journal-title":"Ann Thorac Med"},{"key":"3338_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/1817-1737.69109","volume":"5","author":"BHS Hassan Mahboub","year":"2010","unstructured":"Hassan Mahboub BHS, Santhakumar S, Soriano JB, Pawankar R. Asthma insights and reality in the United Arab Emirates. Ann Thorac Med. 2010;5:217\u201321.","journal-title":"Ann Thorac Med"},{"key":"3338_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-022-00085-5","volume":"8","author":"A Alzaabi","year":"2022","unstructured":"Alzaabi A, Al Busaidi N, Pradhan R, et al. Over-prescription of short-acting \u03b2(2)-agonists and asthma management in the Gulf region: a multicountry observational study. Asthma Res Pract. 2022;8:3.","journal-title":"Asthma Res Pract"},{"key":"3338_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02008-9","volume":"22","author":"A Yorganc\u0131o\u011flu","year":"2022","unstructured":"Yorganc\u0131o\u011flu A, Aksu K, Nayc\u0131 SA, et al. Short-acting \u03b2(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III. BMC Pulm Med. 2022;22:216.","journal-title":"BMC Pulm Med"},{"key":"3338_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/02770903.2022.2082305","volume":"60","author":"F Montero-Arias","year":"2023","unstructured":"Montero-Arias F, Garcia JCH, Gallego MP, et al. Over-prescription of short-acting \u03b2(2)-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study. J Asthma. 2023;60:574\u201387.","journal-title":"J Asthma"},{"key":"3338_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price DB, Trudo F, Voorham J, et al. Adverse outcomes\nfrom initiation of systemic corticosteroids\nfor asthma: long-term observational study. J\nAsthma Allergy. 2018;11:193\u2013204.","journal-title":"J Asthma Allergy"},{"key":"3338_CR37","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","volume":"10","author":"CM Porsbjerg","year":"2022","unstructured":"Porsbjerg CM, Menzies-Gow AN, Tran TN, et al. Global variability in administrative approval prescription criteria for biologic therapy in severe asthma. J Allergy Clin Immunol Pract. 2022;10:1202\u201316.e23.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3338_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4168\/aair.2022.14.3.300","volume":"14","author":"JW Kwon","year":"2022","unstructured":"Kwon JW, Kim MA, Sim DW, et al. Prescription patterns of oral corticosteroids for asthma treatment and related asthma phenotypes in university hospitals in Korea. Allergy Asthma Immunol Res. 2022;14:300\u201313.","journal-title":"Allergy Asthma Immunol Res"},{"key":"3338_CR39","doi-asserted-by":"crossref","unstructured":"Carriero V, Bertolini F, Arrigo E, Ricciardolo FLM. Eosinophilic refractory inflammation in OCS dependent severe asthma. Eur Resp J. 2021;58(suppl 65):PA1103.","DOI":"10.1183\/13993003.congress-2021.PA1103"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03338-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:44Z","timestamp":1762030964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03338-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3338"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03338-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sevim Bavbek has given lectures at meetings supported by AstraZeneca, GSK, and Novartis, and reports receipt of advisory board fees from AstraZeneca, GSK, and Novartis. Mona Al-Ahmad has received lecture and advisory board honoraria from AstraZeneca, GSK, Novartis, and Sanofi. Hala Samaha has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Pooran Chand Kathuria has no conflicts of interest to report. Patricia Fernandez reports having been a speaker for AstraZeneca, GSK, Sanofi, and Teva, and participated in advisory boards with AstraZeneca, GSK, and Sanofi. Nasser Al Busaidi has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Tayseer Ibrahim has received lecture honoraria from AstraZeneca, GSK, and Sanofi. Bassam Mahboub has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Seema Haider and Gur Levy are employed by and hold financial equities in GSK. Saeed Noibi is employed by GSK. Riyad Omar Al-Lehebi has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, GSK, and Sanofi, and received advisory board fees from GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by an institutional review board, and the study was conducted in accordance with the International Council on Harmonisation, Good Pharmacoepidemiology Practice, Good Clinical Practice, and all applicable patient privacy requirements and country-specific requirements relevant for an observational study. Data were collected from existing medical records and ethical committee reviews were conducted for all included countries. Informed consent to participate was obtained for patients in countries where a waiver for informed consent was not requested or granted. The data collected were anonymized and non-identifiable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}